Brentuximab in the Treatment of CD30-Positive Enteropathy-Associated T-Cell Lymphoma
Enteropathy-associated T-cell lymphoma (EATL) is a rare aggressive lymphoma that confers a poor prognosis with current treatment strategies. Given the rarity of this disease, prospective randomized trials are limited, andthus a standard validated treatment strategy is lacking. This report presents the disease course of a patient with EATL who was treated with single-agent brentuximab vedotin (BV), an anti-CD30 conjugated antibody.
Target Audience
This activity has been designated to meet the educational needs of physicians and nurses involved in the management of patients with cancer.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Describe the rationale for the management methods used in this case presentation
- Describe the ideal management of a patient taking brentuximab for the treatment of CD30-positive enteropathy-associated T-cell lymphoma
Waleed F. Khalaf, MD
Division of Hematology/Oncology,Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee
Meghan E. Caldwell, ACNP
Division of Hematology/Oncology,Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee
Nishitha Reddy, MD, MSCI
Division of Hematology/Oncology,Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee
Available Credit
- 1.00 Participation
- 1.00 Nurse
- 1.00 Physician